Biosensors market in 2025 is driven by advanced healthcare applications, dominated by oxidoreductase enzymes and non-wearable ...

Investing.com - Abbott Laboratories (NYSE:ABT) has backed its full-year financial guidance despite noting a period of ...

The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with ...

The FreeStyle Libre 3 system consists of the sensor around the size of a £1 coin that is worn on the upper arm and an app which can be used by users to record their real-time glucose levels and ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

The medtech giant recalled FreeStyle Libre 3 sensors after the devices provided incorrect high glucose readings, with the US Food and Drug Administration (FDA) tagging the recall as Class I.

Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S.